科拓生物
(300858)
| 流通市值：31.23亿 | | | 总市值：42.48亿 |
| 流通股本：1.94亿 | | | 总股本：2.63亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 218,714,979.06 | 138,050,858.07 | 59,025,584.73 | 299,241,834.45 |
| 营业收入 | 218,714,979.06 | 138,050,858.07 | 59,025,584.73 | 299,241,834.45 |
| 二、营业总成本 | 152,721,092.56 | 96,896,107.04 | 40,467,617.52 | 209,600,910.79 |
| 营业成本 | 100,297,002.12 | 62,151,307.27 | 26,952,626.55 | 135,909,713.8 |
| 税金及附加 | 2,931,032.24 | 2,284,427.51 | 587,988.5 | 4,918,248.77 |
| 销售费用 | 24,751,458.36 | 15,925,717.01 | 5,462,498.53 | 33,937,227.05 |
| 管理费用 | 20,497,814.45 | 13,458,534.81 | 6,321,141.44 | 24,097,003.54 |
| 研发费用 | 24,045,152.14 | 16,056,661.13 | 8,008,843.89 | 34,194,078.64 |
| 财务费用 | -19,801,366.75 | -12,980,540.69 | -6,865,481.39 | -23,455,361.01 |
| 其中:利息费用 | 239,872.31 | 227,075.29 | 205,016.98 | 500,914.39 |
| 其中:利息收入 | 20,064,354.11 | 13,226,002.28 | 7,078,660.74 | 24,003,601.93 |
| 加:公允价值变动收益 | 1,486,574.28 | 1,282,054.8 | 1,134,383.57 | 1,262,328.77 |
| 加:投资收益 | 1,854,709.79 | 1,478,533 | 280,184.64 | 6,122,192.73 |
| 资产处置收益 | 566,011.33 | 566,011.33 | 568,552.16 | 34,002.85 |
| 信用减值损失(新) | 1,943,339.88 | 1,850,804.34 | -215,116.49 | -1,818,460.45 |
| 其他收益 | 7,938,974.89 | 3,802,616.83 | 1,897,730.53 | 7,360,708.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 79,783,496.67 | 50,134,771.33 | 22,223,701.62 | 102,601,696.28 |
| 加:营业外收入 | 76,067.77 | 44,793.12 | 4,691.54 | 27,126.95 |
| 减:营业外支出 | 176,598.86 | 102,058.85 | 2,055.85 | 587,787.2 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 79,682,965.58 | 50,077,505.6 | 22,226,337.31 | 102,041,036.03 |
| 减:所得税费用 | 8,492,040.88 | 6,562,520.14 | 3,709,892.48 | 8,561,127.03 |
| 六、净利润 | 71,190,924.7 | 43,514,985.46 | 18,516,444.83 | 93,479,909 |
| 持续经营净利润 | 71,190,924.7 | 43,514,985.46 | 18,516,444.83 | 93,479,909 |
| 归属于母公司股东的净利润 | 71,190,924.7 | 43,514,985.46 | 18,516,444.83 | 93,479,909 |
| (一)基本每股收益 | 0.27 | 0.17 | 0.07 | 0.35 |
| (二)稀释每股收益 | 0.27 | 0.17 | 0.07 | 0.35 |
| 九、综合收益总额 | 71,190,924.7 | 43,514,985.46 | 18,516,444.83 | 93,479,909 |
| 归属于母公司股东的综合收益总额 | 71,190,924.7 | 43,514,985.46 | 18,516,444.83 | 93,479,909 |
| 公告日期 | 2024-10-30 | 2024-08-21 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |